TC Biopharm (Holdings) logo

TC Biopharm (Holdings)NASDAQ: TCBP

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United Kingdom

IPO:

11 February 2022

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$304.61 K
-99%vs. 3y high
3%vs. sector
-97%vs. 3y high
0%vs. sector
-99%vs. 3y high
22%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Sat, 16 Nov 2024 00:59:11 GMT
$0.62-$0.10(-14.21%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

TCBP Latest News

TCBP Awarded Non-Dilutive Funding, ScaleReady's G-Rex® Grant
prnewswire.com12 November 2024 Sentiment: POSITIVE

EDINBURGH, Scotland , Nov. 12, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it has been awarded non-dilutive funding of $250,000 from the G-Rex® Grant Program.  The G-Rex® Grant Program, launched by ScaleReady alongside Wilson Wolf Manufacturing and the Bio-Techne Corporation, is a $20M initiative to advance the state of cell and gene-modified cell therapy (CGT) development and manufacturing.

TCBP Provides Shareholder Update and Highlights Recent Milestone Achievements
prnewswire.com30 October 2024 Sentiment: POSITIVE

EDINBURGH, Scotland , Oct. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today provides an update to its shareholders and highlighted the Company's operational achievements thus far in 2024. "The Company has made tremendous strides during the current year and bolstered its standing as a leading clinical-stage biopharmaceutical company," said Bryan Kobel, CEO of TC BioPharm.

TCBP Responds to False Social Media Claim
prnewswire.com25 October 2024 Sentiment: POSITIVE

TC BioPharm remains compliant with all Nasdaq listing requirements and will continue trading on the exchange EDINBURGH, Scotland , Oct. 25, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today refuted a false claim made earlier this week on social media, stating there is absolutely no way the company is in any danger of being delisted from the Nasdaq stock exchange.  The since deleted rumor stated that the company had filed an 8-K Notice to "Delist" from the Nasdaq and would transfer trading to a different exchange.

TCBP Enters Research Planning Collaboration with Dr. Carlos Maluquer de Motes for Mpox Therapeutic
prnewswire.com22 October 2024 Sentiment: POSITIVE

EDINBURGH, Scotland , Oct. 22, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced it has entered into a research planning collaboration with Dr. Carlos Maluquer de Motes for the development of a treatment for Monkeypox. Dr. Carlos Maluquer de Motes is Reader and Principal Investigator at the University of Surrey, United Kingdom and works closely with The Pirbright Institute, a leading center of excellence in research of viral diseases that spread from animals to humans.

TCBP Announces Artificial Intelligence Initiative with Partner Carnegie Mellon University for Donor Screening
prnewswire.com03 October 2024 Sentiment: POSITIVE

TC BioPharm Limited is partnering with Dr. Wei Wu of Carnegie Mellon University to create an artificial intelligence solution to optimize the donor screening and matching process The software could have additional applications across cell therapy for donor/patient matching EDINBURGH, Scotland , Oct. 3, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced it has entered into a sponsored research agreement with Carnegie Mellon University to explore the potential use of artificial intelligence to optimize the patient screening process. The Company will partner with Dr. Wei Wu, a faculty member in the Ray and Stephanie Lane Computational Biology Department within the School of Computer Science at the renowned university, and her lab to leverage AI to build a solution that enhances the donor selection process and matching process.

TCBP Announces Site Opening of Guys and St. Thomas Hospital
prnewswire.com25 September 2024 Sentiment: POSITIVE

Additional London-based clinic to increase enrolment velocity Leading hospital with extensive cell therapy and oncology trial experience EDINBURGH, Scotland , Sept. 25, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced new site opening of Guys and St. Thomas Hospital in the ACHIEVE UK Trial.

TCBP Announces First Patient Completed the Full Fose Regimen in ACHIEVE Clinical Trial
prnewswire.com12 September 2024 Sentiment: POSITIVE

No TCB008-related Adverse Events seen in any of the re-start patients 6 Patients received second dose, 3 Patients received third dose, 1 Patient received fourth dose EDINBURGH, Scotland, Sept. 12, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announces the first patient has completed the full dose regimen in the ACHIEVE Phase 2b trial ongoing in the UK with no drug related Adverse Events seen in any of the re start patients.

TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox
prnewswire.com09 September 2024 Sentiment: POSITIVE

EDINBURGH, Scotland , Sept. 9, 2024  /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it intends to begin Proof of Concept preclinical studies for its lead therapeutic TCB 008, for treatment in monkey pox.

TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox
prnewswire.com06 September 2024 Sentiment: POSITIVE

EDINBURGH, Scotland , Sept. 6, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it intends to begin Proof of Concept preclinical studies for its lead therapeutic TCB 008, for treatment in monkey pox.

TCBP Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
prnewswire.com05 September 2024 Sentiment: POSITIVE

EDINBURGH, Scotland , Sept. 5, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications today announced it will participate at the H.C.

What type of business is TC Biopharm (Holdings)?

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

What sector is TC Biopharm (Holdings) in?

TC Biopharm (Holdings) is in the Healthcare sector

What industry is TC Biopharm (Holdings) in?

TC Biopharm (Holdings) is in the Biotechnology industry

What country is TC Biopharm (Holdings) from?

TC Biopharm (Holdings) is headquartered in United Kingdom

When did TC Biopharm (Holdings) go public?

TC Biopharm (Holdings) initial public offering (IPO) was on 11 February 2022

What is TC Biopharm (Holdings) website?

https://tcbiopharm.com

Is TC Biopharm (Holdings) in the S&P 500?

No, TC Biopharm (Holdings) is not included in the S&P 500 index

Is TC Biopharm (Holdings) in the NASDAQ 100?

No, TC Biopharm (Holdings) is not included in the NASDAQ 100 index

Is TC Biopharm (Holdings) in the Dow Jones?

No, TC Biopharm (Holdings) is not included in the Dow Jones index

When was TC Biopharm (Holdings) the previous earnings report?

No data

When does TC Biopharm (Holdings) earnings report?

Next earnings report date is not announced yet